Ting Wang advises Chinese and multinational clients on corporate matters including securities offerings in Hong Kong and New York, cross-border mergers and acquisitions. Mr. Wang also has experience with structured financial products (credit default swaps and collateralized debt obligations).
Prior to joining Paul Hastings, Mr. Wang practiced with another leading international law firm in Washington, D.C., Hong Kong and Beijing. He has also clerked for Judge John M. Walker, Jr., U.S. Court of Appeals for the Second Circuit; Judge Dora L. Irizarry, U.S. District Court for the Eastern District of New York; and Judge George B. Daniels, U.S. District Court for the Southern District of New York.
As the coordinator for law and economics initiatives at the National Committee on U.S.-China Relations, Mr. Wang launched several Track II dialogues on the rule of law and economics between the two countries. As an honors intern at the U.S. Department of the Treasury, he advised the Treasury Secretary on legal matters relating to the World Bank, International Monetary Fund and the Committee on Foreign Investment in the United States (CFIUS).
Mr. Wang received his A.B. (magna cum laude) in Government and A.M. in Regional Studies East Asia from Harvard University and J.D. from Yale Law School. He is a member of New York, District of Columbia and New Jersey bars. He is a native speaker of English and Mandarin Chinese and is conversant in French.
Yale Law School, J.D., 2005
Harvard University, A.B.-A.M., 2002
A pioneering molecular diagnostics technology company with operations across the greater China region in its initial public offering on the Main Board of the Hong Kong Stock Exchange (SEHK) under Chapter 18A of the SEHK Listing Rules for biotech companies.
A leading mainland China based provider of genetic testing services and developer of testing kits in its initial public offering on the Main Board of the SEHK.
Fosun Pharma in in its equity investment in BioNTech SE and in its development and licensing agreement with BioNTech SE to co-develop and commercialize vaccines in China to prevent the Coronavirus Disease 2019 (COVID-19) and related vaccine supply and distribution agreements.
Fosun Pharma in its investment agreement with the New Frontier Corporation and TPG that created New Frontier Health Corporation, the holding company of United Family Healthcare, one of the largest and most recognized integrated premium private healthcare operators in China.
SinoMab BioScience Limited, a developer and producer of emerging therapeutics for the treatment of immunological diseases, in its initial public offering on the Main Board of the Hong Kong Stock Exchange (SEHK) under Chapter 18A of the SEHK Listing Rules for biotech companies.
Hollysys Automation Technologies, Ltd., a leading provider of automation solutions for industry and high-speed rail in China, in its shelf registration and follow-on equity offering on the New York Stock Exchange.
Fosun Tourism Group, the owner of Club Med and Atlantis Sanya, in its initial public offering on the Main Board of the Hong Kong Stock Exchange.
SIIC Environment in its listing by introduction on the Main Board of the Hong Kong Stock Exchange.
WNS (Holdings) Ltd. in its follow-on offering of securities on the New York Stock Exchange.
The Special Committee of Yucheng Technologies Ltd. in a going-private delisting buyout.
Baoxin Auto Group Limited in its initial public offering on the Main Board of the Hong Kong Stock Exchange.
NewQuest Capital in its sale of China Hydroelectric Corporation to Shenzhen Energy.
Fosun International Limited in its joint-acquisition (with TPG and Caisse de dépôt et placement du Québec) of Cirque du Soleil.
TPG in its acquisition of Vishal Wholesale Private Limited, the first significant distressed-asset buyout in India and the first entry into India's retail sector by a foreign private equity investor.
A leading Chinese entertainment conglomerate in negotiations with foreign partners for the development of theme parks and location-based entertainment.
China Mengniu Dairy Co. in its strategic investment by Arla Foods.
A leading U.S. multinational in its proposed acquisition of a Japanese chemical company.
A US-based private equity fund in HKIAC arbitration in disputes arising from real estate joint ventures in China, and coordinating strategy for parallel proceedings in CIETAC and the Beijing Fourth People's Intermediate Court. Obtained US$200 million arbitral award and Hong Kong High Court enforcement order. Negotiated settlement and standstill agreement with judgment debtors secured by guarantees and pledge of onshore collateral by affiliates of the judgment debtor, and share pledge and shareholder loan subordination by the controlling shareholder of the judgment debtor.
A leading Chinese reality television production company and a cultural product promotion company in HKIAC arbitration and coordinating strategy for parallel proceedings in Hong Kong High Court, Beijing Intellectual Property Court, and Beijing Chaoyang District Court in the disputes arising from the format licensing rights of The Voice of China.
A Hong Kong-based film company in civil action in California Superior Court and related settlement discussions in a dispute over royalty rights from the films The Teenage Mutant Ninja Turtles I, II and III.
A Hong Kong-based private equity fund in post-merger indemnity claims including preparation for HKIAC arbitration and settlement negotiations.
A Shenzhen-based technology company's share asset protection plan in Hong Kong, China and the British Virgin Islands.
A US commercial real estate management company in dispute with joint venture partner over a landmark project in Shanghai.
China-based film production joint venture investigated by the U.S. Department of Justice and the Securities and Exchange Commission for potential bribery.
US-based real estate investment fund's investigation of fund misappropriation and accounting irregularities at joint venture in China.
A global pharmaceutical company's internal investigation of potential bribery issues at subsidiary operations in China.
A global health products company's internal investigation of regional executives for corporate mismanagement.
A global pharmaceutical company's post-merger anti-bribery and anti-corruption review of newly-acquired China subsidiary.
A foreign-owned power generation company in China's development and implementation of anti-bribery and anti-corruption program.